Home › Research › What the research found › Every row
Every row of the evidence table
One row per finding: what was tested, which way the result went, and how the study was built. The answer by area, and where the studies disagree, are on the main page.
Every row
Filter
Showing 3 of 382 rows. One row per study per exposure: a study that tested two different things appears twice, once for each.
Scroll the table sideways to see every column.
| Exposure | Question | Direction | Outcome measured | Design | People | Effect size, as the source reported it | Source |
|---|---|---|---|---|---|---|---|
| Anti-amyloid antibody Medicines | Treatment |
No direction reported
whyMechanistic multi-omic profiling of blood from three ARIA-positive patients and three matched controls on lecanemab. It describes a clonally expanded cytotoxic CD8+ T-cell signature and estimates no clinical effect. |
Peripheral CD8+ T-cell signature in lecanemab-associated ARIA | case-control study | 6 | not established — pubmed abstract reports no numeric effect size. |
Nature Communications
2026 ✓ Peer-reviewed PMID 41617706 |
| Anticholinergic / benzodiazepine burden Medicines | Treatment | Harm | 180-day mortality | case-control study | 139,103 | 180-day mortality HR 1.41 (95% CI 1.38-1.44) for benzodiazepines; HR 1.16 (95% CI 1.12-1.20) for antipsychotics |
JAMA Network Open
2025 ✓ Peer-reviewed PMID 41085983 |
| Antipsychotics (harms / discontinuation) Medicines | Treatment | Harm | 180-day mortality | case-control study | 139,103 | 180-day mortality HR 1.41 (95% CI 1.38-1.44) for benzodiazepines; HR 1.16 (95% CI 1.12-1.20) for antipsychotics |
JAMA Network Open
2025 ✓ Peer-reviewed PMID 41085983 |